Black scientists, innovators and employees are key to Merck's … – Merck

Worldwide Countries outside of the United States and Canada.
Learn about scientific contributions of Black employees in our company's history and how our diversity initiatives have shaped our legacy of invention
February 2, 2023
Share this article

Susan Jenkins began a long career at Merck in 1957 when she joined Merck Research Laboratories (MRL) as one of its first female Black chemists. She was part of the team that first synthesized ribonuclease. Later, she joined our company’s corporate equal employment affairs department and served as a black university liaison. By the end of her career here, Susan was senior vice president of human resources and was emblematic of how important having Black women leaders in science was to creating an inclusive work environment.
Susan returned to our company almost 50 years later to attend the presentation of the Citation for Chemical Breakthrough award from the American Chemical Society (ACS) division of the History of Chemistry. The Citation for Chemical Breakthrough was awarded in honor of the series of five articles published in the Journal of the American Chemical Society describing the first total synthesis of an enzyme. These articles were authored by Dr. Ralph Hirschmann and his colleagues in 1969, one of whom was Susan.
Merck alumni include numerous prominent Black civil rights leaders, including William “Bill” Bowers. Bill joined our company in 1951 as a technician, a position he held until 1969 when he received a bachelor of science degree in business management from Rutgers University. He earned his degree with assistance from our company’s educational grant program while balancing his full-time job, four children and many leadership positions in his community, including vice president of the Westfield Community Development Corporation.
Bill retired from a project management position at our company in 1993. He was a vocal proponent for civil rights nationally and within our company, having participated in the 1963 March on Washington. He was a co-founder of Black Employees at Merck (BEAM), which later became Merck’s Black Employees Network (BEN) and is known today as LEAD – Merck’s League of Employees of African Descent, which celebrated its 50th anniversary in 2020.
During the late 1940s, Negro League baseball featured a star pitcher named Jimmy Dean. Famous for his sinker-ball, Jimmy pitched for the Philadelphia Stars facing legends like Jackie Robinson and Hank Aaron.
After the integration of Major League Baseball started to draw athletes and fans away from the Negro Leagues, Jimmy returned to school and began working for Merck. Jimmy traveled extensively, put three sons through college and after 33 years, he retired from his position as a technical analyst in 1990.
In 1968, Merck began sponsoring the Technical Training Program (TTP), a non-profit organization in Newark, New Jersey, which offered classes and on-the-job laboratory experience for students interested in pharmaceutical industry careers. TTP primarily targeted young people from educationally and economically disadvantaged backgrounds. Among TTP’s first graduating class were William “Gary” Mickle and Darrell Harris who became laboratory technicians in MRL. Gary would ultimately work in MRL for over 35 years.
In 1968, Merck appointed Lawrence “Larry” Branch vice president of personnel relations, responsible for coordinating and recommending programs for employment, training, and promotion of persons from all minority groups. This new position marked the beginnings of Merck’s Office of Equal Employment Affairs — one of the first in the country to prioritize equity for black employees, among many other initiatives. Over the years, the Office of Equal Employment Affairs continued to evolve, establishing companywide programming to address complex workplace issues such racism, sexism and other barriers to equality. The programming was so successful it served as a model to other corporations, government organizations and community groups.
During the 1980s, Merck was recognized for its leadership in equal opportunity employment. As national politics surrounding affirmative action grew to be more complex, we maintained our focus on welcoming and supporting diverse employees. The 1983 book “The Hundred Best Companies to Work for in America” listed our company as  No. 15, specifically citing our diversity initiatives.
That same year our company’s commitment to equal opportunity earned recognition from the United States Department of Labor with its Exemplary Voluntary Efforts Award. Then in 1989, we were included on Black Enterprise magazine’s first-ever list of the 50 Best Places for Blacks to Work. Ever since, we have maintained a consistent presence on lists praising corporate diversity published by Black Enterprise, Forbes and more.
Merck’s legacy of antimicrobial innovation and action
Here for Good: A lifelong mission against HIV
Acting early in cancer detection
Are you passionate about building a meaningful career? Come work with us!
Our culture and values
It all comes back to saving and improving lives
We operate responsibly every day to enable a safe and healthy future for people and communities globally.
This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.